• CYAD-01 consists of engineered T cells expressing a CAR based on the natural killer group 2, member D receptor (NKG2D), a transmembrane receptor expressed by natural killer cells and some T-cell subsets.
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CYAD-01 BACKGROUND THINK without preconditioning

DEPLETHINK with prior preconditioning
• CYAD-01 consists of engineered T cells expressing a CAR based on the natural killer group 2, member D receptor (NKG2D), a transmembrane receptor expressed by natural killer cells and some T-cell subsets.
• NKG2D binds to 8 ligands frequently expressed on various tumor types [1, 2] : MHC class I chain-related proteins A (MICA) and B (MICB) and Unique long 16 binding proteins (ULBP) 1-6 ligands.
• Preclinically, CYAD-01 have anti-tumor effects beyond direct cancer cell killing [3] by: o Targeting neovasculature expressing NKG2D ligands, o Targeting immunosuppressive cells such as regulatory T cells and myeloidderived suppressor cells expressing NKG2D ligands, o Recruiting and activating macrophages and myeloid cells within the tumor stroma, shifting to an immunostimulatory TME, and o Inducing a long-term memory immune response specific towards tumor antigens.
STUDY DESIGN
• Two separate arms: one in solid tumor and one in hematologic malignancies i.e. AML/MDS and MM.
• Standalone therapy: No bridging therapy, no preconditioning.
• 3+3 design dose escalation with 3 dose-levels (DL) of CYAD-01 (3×10 8 , 1×10 9 , and 3×10 9 cells/injection).
• 3 doses of CYAD-01 every 2 weeks.
• Potential 3 additional doses of CYAD-01 at 1×10 9 cells/injection according the clinical status at first tumor assessment.
• Patients with r/r AML/MDS • Single CYAD-01 injection administered after a preconditioning regimen (cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily for 3 consecutive days).
• 3+3 design with two different intervals between lymphodepletion and CYAD-01 injection and two dose-levels of CYAD-01 (1×10 8 and 3×10 9 cells/injection).
• Potential 3 additional doses of CYAD-01 without preconditioning regimen at 3×10 9 or 3×10 9 cells/injection.
STATUS
• As of Nov 27, 2018, three patients received the CYAD-01 injection following the preconditioning regimen.
• CYAD-01 post standard Cy/Flu preconditioning was well tolerated. No DLT nor critical AEs were reported (uncleaned database).
• The 3 enrolled patients were not yet evaluable for clinical response.
STATUS (hematologic arm)
• 14 patients have been enrolled at three different dose-levels in the hematologic arm: 6 in DL-1, 3 in DL-2 and 5 in DL-3.
• Out of the 8 r/r AML pts enrolled as of July 31, 2018, 7 were evaluable for clinical response (2 at DL-1, 3 at DL-2 and 2 at DL-3) with promising antileukemic activity [ASH 2018 -presentation 902, session 616 -Dec 3, 2018]: -1 complete remission (CR) with partial hematologic recovery (CR h ) in DL-1, who was bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) on day +97 post CYAD-01 and is in durable complete molecular remission (CR MRD-) for more than 1 year (ongoing). -2 CR with incomplete marrow recovery (CR i ; 1 in DL-1 and 1 in DL-3), for 1 month.
-2 patients at DL-2 had disease stabilization with hematologic improvement and bone marrow blasts decrease: one patient for 3 months and with a decrease from 24% to 10% and the second patient for at least 4 months (ongoing) and with a decrease from 9.8% to 5.5%. All responding pts achieved response by day 29 (i.e. after 2 CYAD-01 administrations).
• The 3 MM and the MDS patients, all in DL-1, did not present any sign of clinical activity.
• CYAD-01 as stand alone was overall well tolerated (Table 1) . 1 dose-limiting toxicity (DLT) was reported in DL-3 (CRS grade 4). Only 6 patients experienced treatment-related grade 3/4 adverse events (AE) (uncleaned database).
• CYAD-01 cells and cytokine and chemokine release (e.g. IFN-γ, MCP-1 and SDF-1) in the peripheral blood post CYAD-01 injections were detected by ddPCR method and luminex assay in several patients following injections (Figures 2 and 3 ).
CYAD-01 DEVELOPMENT
• CYAD-01 is currently evaluated in hematologic and solid cancer indications in a comprehensive clinical development plan (Figure 1 ).
• The Open-label Phase I THINK (NCT03018405) study aims at evaluating the safety and clinical activity of CYAD-01 administered as a standalone therapy in patients with various relapsed/refractory (r/r) cancer indications.
• The Open-label Phase I DEPLETHINK (NCT03466320) aims at evaluating the safety and clinical activity of CYAD-01 administered after a preconditioning regimen with the aim to provide a better CYAD-01 engraftment due to the lymphodepletion of host cells, increase tumor NKG2D ligand expression and overcome the immunosuppressive microenvironment.
• The Open-label Phase I EPITHINK (NCT03612739) study aims at assessing the safety of the CYAD-01 treatment administered concurrently with hypomethylating agent (5-azacytidine). Similar to the preconditioning treatment, the epigenetic treatment could contribute to favor engraftment of CYAD-01 cells and increase target antigen expression while better controlling the disease progression of patients early in the treatment.
EPITHINK with concurrent 5-azacytidine STUDY DESIGN
• Treatment-naïve and/or elderly AML patients ineligible for intensive treatment.
• 3+3 design dose escalation with 3 dose-levels of CYAD-01 (1×10 8 , 3×10 8 , and 1×10 9 cells/injection), • 6 cycles of 5-azacytidine (AZA) (75 mg/m²/d x 7 days) every 4 weeks.
• 8 doses of CYAD-01 every 2 weeks administered 48 hours after the end of a chemotherapy cycle.
STATUS
• As of Nov 27, 2018, no patient has yet been enrolled in the EPITHINK study • The study will be initiated in Q1-2019
CONCLUSIONS
• CYAD-01 has shown promising early clinical activity in relapsed/refractory AML [4] with three objective responses.
• The safety profile of CYAD-01 as stand-alone treatment is favorable. As of Nov 27, 2018, the addition of Cy/Flu prior to CYAD-01 injection, while still early, does not increase the related-AEs rate at 1 st cohort (1×10 8 cells/injection).
• In terms of translational research, the THINK trial demonstrated expansion of peripheral CYAD-01 cells and cytokine release following CYAD-01 injections.
• Based on the data obtained with a Cy/Flu preconditioning in solid tumor indications (not shown here), cell kinetics data in the DEPLETHINK and EPITHINK study are expected to show increased expansion and persistence of the CYAD-01, potentially leading to higher clinical benefit rates. Clinical evaluation with schedule optimization w/o preconditioning is also currently tested. 
